Previous Study: BCIRG 002
Next Study: BCIRG 005
Studies & Results
BCIRG 004
Clinical protocol for a phase II double-blind evaluation of G-CSF vs the optimal schedule of SC-70935 in patients with breast cancer receiving chemotherapy with docetaxel, doxorubicin and cyclophosphamide (TAC)
Presentations
ASCO Annual Meeting, 2001
Mackey JR, Cantin J, Chang J, et al
Role of hematopoietic growth factors in the prevention of neutropenic complications for breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide (TAC): results of a randomized double-blind phase III trial - BCIRG 004.
Publications
Nabholtz J-M, Cantin J, Chang J, et al: Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Clin Breast Cancer 3:268–275, 2002
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
ASCO Annual Meeting, 2001
Mackey JR, Cantin J, Chang J, et al
Role of hematopoietic growth factors in the prevention of neutropenic complications for breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide (TAC): results of a randomized double-blind phase III trial - BCIRG 004.
Publications
Nabholtz J-M, Cantin J, Chang J, et al: Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 3:268–275, 2002
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org